Clinical trial NCT01203306: Bevacizumab Plus Somatostatin Analogue and Metronomic Capecitabine in Patients With Advanced Neuroendocrine Tumors
Official title: Phase II Study of the Combination of Bevacizumab Plus Somatostatin Analogue and Metronomic Capecitabine in Patients With Advanced Inoperable Well-Differentiated Neuroendocrine Tumors
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Neuroendocrine Carcinomas
Keywords: bevacizumab
somatostatin analogue
metronomic capecitabine
neuroendocrine tumors
Lead sponsor: University of Turin, Italy
Sponsor class: OTHER
First posted: 2010-09-16
Enrollment: 42
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Well differentiated neuroendocrine (NE) carcinomas have low proliferative activity and conventional chemotherapy is not recommended. Metronomic chemotherapy, i.e. the frequent administration of cytotoxic drugs at low doses, has demonstrated antiangiogenetic properties. Since well differentiated NE carcinomas are highly vascular, there is a rationale for testing metronomic chemotherapy and antiangiogenetic drugs. This is a national, multicenter, phase II study.

Detailed description: Metastatic or locally advanced well differentiated neuroendocrine carcinoma will be treated with a combination of bevacizumab (5 mg/kg) plus octreotide LAR (long- acting release) 20/30 mg plus capecitabine administered on a metronomic schedule (2000 mg/day).

Patients with stable disease, complete or partial response will continue treatment until progressive disease or unacceptable toxicity.

Primary endpoint: the response to treatment, evaluated according to the RECIST criteria.

Secondary endpoint: - toxicity, graded according to the NCI-CTG criteria;

* symptomatic response: evaluated according to the changes in both the frequency and intensity of symptoms;
* biochemical response: evaluated considering the changes in the tumor marker levels (circulating Chromogranin A);
* relationship between vascular endothelial growth factor (VEGF) polymorphisms and response to treatment;
* time to progression and survival: measured from the date of treatment start to the date of progression and the date of last follow-up or death, respectively.

Eligibility criteria: Inclusion Criteria:

* Histologically or cytologically diagnosis of well-differentiated neuroendocrine carcinoma
* Inoperable disease
* Age \> 18
* ECOG Performance Status 0-2
* Life expectancy of at least 12 weeks
* Measurable and/or evaluable lesions according to RECIST criteria
* Radiological documentation of disease progression
* Adequate bone marrow reserve
* Adequate hepatic and renal function
* Urine dipstick of proteinuria \< 2+
* Written informed consent
* Comply with the protocol procedures

Exclusion criteria:

* Serious non-healing wound or ulcer
* Evidence of bleeding diathesis or coagulopathy
* Uncontrolled hypertension
* Clinically significant cardiovascular disease for example cerebrovascular accidents (≤6 months), myocardial infarction (≤6 months), unstable angina, New York Heart Association (NYHA) grade II or greater congestive heart failure, serious cardiac arrhythmia requiring medication
* Current or recent ongoing treatment with anticoagulants for therapeutic purposes
* Chronic, daily treatment with high-dose aspirin (\>325 mg/day) or other medications known to predispose to gastrointestinal ulceration
* Patients with severe renal impairment (creatinine clearance below 30 ml/min)
* Other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or cervical cancer in situ
* Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study treatment start, or anticipation of the need for major surgical procedure during the course of the study
* Pregnant or lactating women.

Primary outcomes:
measure: time to progression
timeFrame: 36 months
Secondary outcomes:
measure: Toxicity
timeFrame: two years
measure: Time to Treatment Failure (TTF)
timeFrame: two years
measure: Overall survival (OS)
timeFrame: 48 months
Other outcomes:
Locations:
city: San Giovanni Rotondo
country: Italy
facility: Lucia Tozzi
state: Foggia
city: Orbassano
country: Italy
facility: Anna Ferrero
state: Turin
city: Bologna
country: Italy
facility: Elisabetta Nobili
city: Milan
country: Italy
facility: Nicola Fazio
city: Turin
country: Italy
facility: Enrica Milanesi
Study officials:
affiliation: Medical Oncology, Department of Clinical and Biological Sciences, University of Turin
name: Alfredo Berruti, MD, PhD
role: STUDY_DIRECTOR
References:
citation: Brizzi MP, Berruti A, Ferrero A, Milanesi E, Volante M, Castiglione F, Birocco N, Bombaci S, Perroni D, Ferretti B, Alabiso O, Ciuffreda L, Bertetto O, Papotti M, Dogliotti L. Continuous 5-fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte oncology network. BMC Cancer. 2009 Nov 3;9:388. doi: 10.1186/1471-2407-9-388.
citation: Berruti A, Fazio N, Ferrero A, Brizzi MP, Volante M, Nobili E, Tozzi L, Bodei L, Torta M, D'Avolio A, Priola AM, Birocco N, Amoroso V, Biasco G, Papotti M, Dogliotti L. Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the XELBEVOCT study. BMC Cancer. 2014 Mar 14;14:184. doi: 10.1186/1471-2407-14-184.